ºüÀêÊÓƵ

Divis earned $3.1 million last year, according to a filed last week, up from $1.4 million in 2019.

Stock options valued at $2.2 million were the biggest part of Divis' compensation. He also received a 4% salary raise to $520,000 and a $353,600 bonus that was 112.5% of his target amount. The bonus was based on progress with Avadel's narcolepsy treatment, known as FT218, among other measures. The company that it submitted a new drug application for FT218 to the Food and Drug Administration.

In August, Avadel also granted executives performance-based stock units tied to gaining regulatory approval for FT218. For Divis, those units have a maximum value of $1.4 million, but the company did not include them in his pay tally because "achievement was not probable on the grant date."

The CEO's perquisites included a $12,000 auto allowance.

Divis earned 10 times as much as the median Avadel employee, whose pay was calculated at $327,187.

Chesterfield-based Avadel reported a last year after losing $33 million in 2019. Its share price fell 12% last year.

Here's what ºüÀêÊÓƵ CEOs earned in 2019: